Search

Author/Creator Akhurst, Tim

2. Nodal metabolic tumour volume on baseline 18F‐FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative‐intent chemoradiotherapy/radiotherapy. Issue 6 (28th July 2021)

Authors:
Alipour, Ramin; Bucknell, Nick; Bressel, Mathias; Everitt, Sarah; MacManus, Michael; Siva, Shankar; Hofman, Michael S; Akhurst, Tim; Hicks, Rodney J; Iravani, Amir
Journal:
Journal of medical imaging and radiation oncology
Issue:
Volume 65:Issue 6(2021)
Page Start:
748
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei. Issue 7 (July 2022)

Authors:
Flood, Michael P.; Kong, Joseph C.; Pham, Toan; Waters, Peadar S.; Soucisse, Mikael; Ramsay, Robert; Wong, Hui-Li; Mitchell, Catherine; Michael, Michael; McCormick, Jacob J.; Warrier, Satish K.; Akhurst, Tim; Heriot, Alexander G.
Journal:
European journal of surgical oncology
Issue:
Volume 48:Issue 7(2022)
Page Start:
1606
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. Issue 11 (18th November 2022)

Authors:
Hegi-Johnson, Fiona; Rudd, Stacey E; Wichmann, Christian; Akhurst, Tim; Roselt, Peter; Trinh, Jenny; John, Thomas; Devereux, Lisa; Donnelly, Paul S; Hicks, Rod; Scott, Andrew M; Steinfort, Daniel; Fox, Stephen; Blyth, Benjamin; Parakh, Sagun; Hanna, Gerard G; Callahan, Jason; Burbury, Kate; MacMa...
Journal:
BMJ open
Issue:
Volume 12:Issue 11(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Issue 11 (November 2022)

Authors:
Buteau, James P; Martin, Andrew J; Emmett, Louise; Iravani, Amir; Sandhu, Shahneen; Joshua, Anthony M; Francis, Roslyn J; Zhang, Alison Y; Scott, Andrew M; Lee, Sze-Ting; Azad, Arun A; McJannett, Margaret M; Stockler, Martin R; Williams, Scott G; Davis, Ian D; Hofman, Michael S; Akhurst, Tim; Ali...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 11(2022)
Page Start:
1389
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapy. Issue 1 (July 2017)

Authors:
Ashley Cox, Richard; Akhurst, Tim; Bressel, Mathias; MacManus, Michael; Ball, David
Journal:
Radiotherapy and oncology
Issue:
Volume 124:Issue 1(2017:Jul.)
Page Start:
25
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Issue 6 (June 2018)

Authors:
Hofman, Michael S; Violet, John; Hicks, Rodney J; Ferdinandus, Justin; Thang, Sue Ping; Akhurst, Tim; Iravani, Amir; Kong, Grace; Ravi Kumar, Aravind; Murphy, Declan G; Eu, Peter; Jackson, Price; Scalzo, Mark; Williams, Scott G; Sandhu, Shahneen
Journal:
Lancet oncology
Issue:
Volume 19:Issue 6(2018)
Page Start:
825
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗